Neurocrine Biosciences, Inc. (NASDAQ:NBIX)‘s stock had its “buy” rating reaffirmed by stock analysts at Citigroup Inc. in a research note issued to investors on Thursday, November 2nd, The Fly reports. They presently have a $79.00 price target on the stock. Citigroup Inc.’s price objective would indicate a potential upside of 6.48% from the company’s current price.
NBIX has been the topic of a number of other reports. BMO Capital Markets boosted their price objective on Neurocrine Biosciences from $75.00 to $84.00 and gave the company an “outperform” rating in a research note on Friday, August 4th. Piper Jaffray Companies set a $68.00 price objective on Neurocrine Biosciences and gave the company a “buy” rating in a research note on Thursday, August 24th. BidaskClub raised Neurocrine Biosciences from a “hold” rating to a “buy” rating in a report on Wednesday, August 9th. Needham & Company LLC reaffirmed a “buy” rating and set a $58.00 target price on shares of Neurocrine Biosciences in a report on Sunday, September 17th. Finally, Oppenheimer Holdings, Inc. reaffirmed a “buy” rating and set a $70.00 target price on shares of Neurocrine Biosciences in a report on Thursday, September 7th. One analyst has rated the stock with a hold rating and eighteen have given a buy rating to the company’s stock. Neurocrine Biosciences has an average rating of “Buy” and an average target price of $78.88.
Neurocrine Biosciences (NASDAQ:NBIX) opened at $74.19 on Thursday. Neurocrine Biosciences has a 52 week low of $37.35 and a 52 week high of $75.98. The company has a quick ratio of 14.37, a current ratio of 14.38 and a debt-to-equity ratio of 1.05.
Neurocrine Biosciences (NASDAQ:NBIX) last released its earnings results on Wednesday, November 1st. The company reported ($0.13) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.49) by $0.36. The business had revenue of $60.77 million for the quarter, compared to the consensus estimate of $29.38 million. During the same quarter in the previous year, the firm earned ($0.43) earnings per share. equities analysts predict that Neurocrine Biosciences will post -1.74 earnings per share for the current year.
In related news, insider Christopher Flint Obrien sold 6,925 shares of the company’s stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $61.04, for a total transaction of $422,702.00. Following the completion of the transaction, the insider now owns 55,898 shares in the company, valued at $3,412,013.92. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Kyle Gano sold 24,818 shares of the company’s stock in a transaction that occurred on Thursday, November 2nd. The shares were sold at an average price of $71.05, for a total value of $1,763,318.90. Following the transaction, the insider now owns 84,596 shares of the company’s stock, valued at approximately $6,010,545.80. The disclosure for this sale can be found here. Insiders sold 150,710 shares of company stock valued at $9,758,593 in the last quarter. Corporate insiders own 4.80% of the company’s stock.
A number of hedge funds have recently modified their holdings of the stock. FMR LLC grew its stake in Neurocrine Biosciences by 9.8% in the second quarter. FMR LLC now owns 13,211,023 shares of the company’s stock worth $607,707,000 after purchasing an additional 1,180,874 shares during the period. Vanguard Group Inc. grew its stake in shares of Neurocrine Biosciences by 2.8% in the second quarter. Vanguard Group Inc. now owns 6,922,294 shares of the company’s stock worth $318,426,000 after acquiring an additional 186,329 shares during the last quarter. Janus Henderson Group PLC grew its stake in shares of Neurocrine Biosciences by 2.6% in the third quarter. Janus Henderson Group PLC now owns 5,507,763 shares of the company’s stock worth $337,516,000 after acquiring an additional 140,639 shares during the last quarter. BlackRock Inc. grew its stake in shares of Neurocrine Biosciences by 14,216.0% in the first quarter. BlackRock Inc. now owns 5,031,933 shares of the company’s stock worth $217,884,000 after acquiring an additional 4,996,784 shares during the last quarter. Finally, Perceptive Advisors LLC grew its stake in shares of Neurocrine Biosciences by 33.9% in the third quarter. Perceptive Advisors LLC now owns 4,791,589 shares of the company’s stock worth $293,629,000 after acquiring an additional 1,214,000 shares during the last quarter.
Neurocrine Biosciences Company Profile
Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.
Receive News & Ratings for Neurocrine Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences Inc. and related companies with our FREE daily email newsletter.